Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Mechanisms of immunotherapy resistance: lessons from glioblastoma.

Jackson CM, Choi J, Lim M.

Nat Immunol. 2019 Sep;20(9):1100-1109. doi: 10.1038/s41590-019-0433-y. Epub 2019 Jul 29. Review.

PMID:
31358997
2.

Immunomodulation for glioblastoma.

Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH.

Curr Opin Neurol. 2017 Jun;30(3):361-369. doi: 10.1097/WCO.0000000000000451. Review.

PMID:
28368867
3.

Immunotherapies for malignant glioma.

Boussiotis VA, Charest A.

Oncogene. 2018 Mar;37(9):1121-1141. doi: 10.1038/s41388-017-0024-z. Epub 2017 Dec 15. Review.

4.

Emerging treatment strategies for glioblastoma multiforme.

Carlsson SK, Brothers SP, Wahlestedt C.

EMBO Mol Med. 2014 Nov;6(11):1359-70. doi: 10.15252/emmm.201302627. Review.

5.

Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.

Chin C, Lunking ES, de la Fuente M, Ayad NG.

Front Oncol. 2018 Nov 13;8:521. doi: 10.3389/fonc.2018.00521. eCollection 2018. Review.

6.

Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.

Miranda A, Blanco-Prieto M, Sousa J, Pais A, Vitorino C.

Int J Pharm. 2017 Oct 5;531(1):372-388. doi: 10.1016/j.ijpharm.2017.07.056. Epub 2017 Jul 27. Review.

PMID:
28755993
7.

Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.

Okonogi N, Shirai K, Oike T, Murata K, Noda SE, Suzuki Y, Nakano T.

Anticancer Res. 2015 Mar;35(3):1229-35. Review.

PMID:
25750269
8.

New Directions in the Treatment of Glioblastoma.

Reitman ZJ, Winkler F, Elia AEH.

Semin Neurol. 2018 Feb;38(1):50-61. doi: 10.1055/s-0038-1623534. Epub 2018 Mar 16. Review.

PMID:
29548052
9.

Dendritic cell immunotherapy for malignant gliomas.

Luptrawan A, Liu G, Yu JS.

Rev Recent Clin Trials. 2008 Jan;3(1):10-21. Review.

PMID:
18474011
10.

Mechanisms regulating glioma invasion.

Paw I, Carpenter RC, Watabe K, Debinski W, Lo HW.

Cancer Lett. 2015 Jun 28;362(1):1-7. doi: 10.1016/j.canlet.2015.03.015. Epub 2015 Mar 18. Review.

11.

Immunological Aspects of Malignant Gliomas.

Cohen-Inbar O, Zaaroor M.

Can J Neurol Sci. 2016 Jul;43(4):494-502. doi: 10.1017/cjn.2016.34. Review.

PMID:
27324313
12.

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Neagu MR, Reardon DA.

Curr Treat Options Oncol. 2015 Nov;16(11):54. doi: 10.1007/s11864-015-0371-3. Review.

PMID:
26454859
13.

The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.

Paff M, Alexandru-Abrams D, Hsu FP, Bota DA.

Hum Vaccin Immunother. 2014;10(11):3322-31. doi: 10.4161/21645515.2014.983002. Review.

14.

New perspectives in glioma immunotherapy.

Daga A, Bottino C, Castriconi R, Gangemi R, Ferrini S.

Curr Pharm Des. 2011;17(23):2439-67. Review.

PMID:
21827420
15.

Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.

Conti S, Vexler A, Edry-Botzer L, Kalich-Philosoph L, Corn BW, Shtraus N, Meir Y, Hagoel L, Shtabsky A, Marmor S, Earon G, Lev-Ari S.

PLoS One. 2018 Jul 3;13(7):e0198627. doi: 10.1371/journal.pone.0198627. eCollection 2018.

16.

Long Non-Coding RNAs Dysregulation and Function in Glioblastoma Stem Cells.

Zhang X, Kiang KM, Zhang GP, Leung GK.

Noncoding RNA. 2015 Jun 3;1(1):69-86. doi: 10.3390/ncrna1010069. Review.

17.

Salinomycin's potential to eliminate glioblastoma stem cells and treat glioblastoma multiforme (Review).

Magrath JW, Kim Y.

Int J Oncol. 2017 Sep;51(3):753-759. doi: 10.3892/ijo.2017.4082. Epub 2017 Jul 27. Review.

PMID:
28766685
18.

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

Polivka J Jr, Polivka J, Holubec L, Kubikova T, Priban V, Hes O, Pivovarcikova K, Treskova I.

Anticancer Res. 2017 Jan;37(1):21-33. Review.

PMID:
28011470
19.

Mechanisms of immunomodulation in human glioblastoma.

Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V.

Immunotherapy. 2011 Apr;3(4 Suppl):42-4. doi: 10.2217/imt.11.39. Review.

PMID:
21524170
20.

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J.

Cancer. 1995 Sep 1;76(5):840-52.

PMID:
8625188

Supplemental Content

Support Center